Archives
Epalrestat Workflows for Polyol Pathway Research
2026-09-09
Epalrestat provides a practical way to interrogate aldose reductase, polyol pathway flux, and redox responses across diabetic neuropathy research, neuroprotection, and exploratory cancer metabolism studies. This guide combines preparation parameters, assay workflows, cross-domain interpretation, and troubleshooting for reproducible oxidative stress research.
Baicalin: Pathways, Plasticity, and Cancer Research
2026-09-09
Baicalin is a Scutellaria baicalensis flavone glycoside with reported KEAP1-NRF2/HO-1 pathway modulation and preclinical activity in visual cortical plasticity and cancer research. A 2026 NeuroImage study found that 10 mg/kg baicalin restored ocular dominance plasticity in adult amblyopic mice, while the product dossier reports additional oncology-related pathway applications.
How GCG Disrupts SARS-CoV-2 Nucleocapsid Condensation
2026-09-08
The reference study identifies RNA-driven liquid–liquid phase separation of the SARS-CoV-2 nucleocapsid protein as a mechanistic step in viral biology. It further shows that the green-tea polyphenol (-)-gallocatechin gallate disrupts this condensation process and suppresses viral replication, providing a framework for studying viral condensates as chemical intervention points.
DFCP1, ATGL, and Starvation-Driven Lipolysis
2026-09-07
The reference study identifies DFCP1/ZFYVE1 as a nutrient-sensitive regulator of lipid droplet catabolism and defines its direct effect on ATGL behavior during starvation. Its key mechanistic insight is that DFCP1 recruits and retains ATGL on lipid droplets, limiting the dynamic lipase exchange required for efficient lipolysis.
Gamithromycin: From Ribosome to Translational Strategy
2026-09-07
Gamithromycin, also known as ML-1709460, is more than a macrolide antibiotic catalog entry: its value lies in the connection between 50S ribosomal inhibition, pulmonary exposure, and AUC24h/MIC-driven pharmacodynamics. This thought-leadership article translates the available rabbit pasteurellosis evidence into practical guidance for veterinary infection models, assay design, and translational development.
Metformin HCl as a Translational Immunometabolism Tool
2026-09-05
Metformin Hydrochloride is more than a glucose-metabolism reagent. Its linked effects on hepatic gluconeogenesis, AMPK–ACC signaling, lipid handling, and cellular redox create a strategic framework for connecting metabolic perturbation with immune-function assays. This article outlines how translational researchers can validate that bridge without overstating the evidence.
Panobinostat-Induced Calcineurin Degradation in Myeloma
2026-09-04
The reference study identifies calcineurin catalytic subunit PPP3CA as a therapeutically relevant target of panobinostat in multiple myeloma. Its experiments connect PPP3CA abundance with advanced disease and bortezomib resistance, while showing that calcineurin-directed combinations can improve antimyeloma activity and suppress osteoclast formation.
From Thermal Shifts to Translational Insight
2026-09-04
Translational research increasingly depends on connecting phenotypic activity with direct evidence of ligand engagement. This thought-leadership article shows how thermal shift assay logic, orthogonal validation, and the DiscoveryProbe™ Bioactive Compound Library Plus (SKU: L1022P) can help researchers move from broad screening to defensible mechanism-of-action hypotheses.
Faropenem Sodium: Workflow for PK and AMR Studies
2026-09-04
Faropenem sodium supports integrated antimicrobial, anaerobe, resistance, and renal transport workflows rather than a single endpoint assay. Its PBP-directed activity and Npt1-associated secretion profile allow researchers to connect bacterial inhibition with disposition-oriented experiments.
Toremifene Citrate: ER Assay Workflows
2026-09-03
Build more interpretable estrogen receptor experiments with Toremifene Citrate, from receptor-binding benchmarks to breast cancer cell proliferation and translational rodent studies. This workflow emphasizes concentration design, vehicle control, exposure timing, and troubleshooting for reliable hormone receptor modulation.
SR 11302: Translating AP-1 Blockade to Oncology
2026-09-02
A translational perspective on SR 11302 as a selective AP-1 transcription factor inhibitor, connecting tumor-cell assays, AP-1-driven chemoprevention, and emerging immune-context studies while defining the evidence needed for rigorous oncology development.
Protease Inhibitor Cocktail for OXPHOS Workflows
2026-09-02
Protect fragile signaling and mitochondrial proteins from extraction-related degradation with an EDTA-free, broad-spectrum formulation. This workflow connects controlled lysate preparation to Western blotting, Co-IP, kinase assays, and mechanistic OXPHOS studies involving LRPPRC inhibition and Dasatinib.
Ruxolitinib: Mechanism-First Immune Assay Design
2026-09-01
Ruxolitinib (INCB018424) is more than a JAK1/2 inhibitor: it is a practical tool for connecting pathway control with high-dimensional immune phenotyping. This guide translates its biochemical profile and recent murine sarcoma findings into better assay design, controls, and interpretation.
Rucaparib: A Causal Framework for DDR Assays
2026-09-01
Rucaparib (AG-014699) is a potent PARP1 inhibitor for dissecting DNA repair stress, radiosensitization, and cell-fate decisions. This article presents a causal assay framework that separates target engagement, persistent DNA breaks, transcriptional effects, and apoptosis.
Relative Versus Fractional Viability in Cancer Studies
2026-08-31
Hannah Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that growth inhibition and cell death are related but non-equivalent drug-response phenotypes. This framework improves interpretation of in vitro cancer pharmacology by incorporating response magnitude, composition, and timing rather than treating a single viability endpoint as a complete measure of cytotoxicity.
579 records 7/39 page Previous Next First page 上5页 678910 下5页 Last page